NCT07586449Not yet recruiting
A Prospective Observational Study of Senaparib in the Treatment of Epithelial Ovarian Cancer
Evaluation of Safety and Effectiveness of Senaparib in Epithelial Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer: A Prospective Observational Real-World Study
Source: ClinicalTrials.gov · Last updated 14 May 2026
Brief summary (registry, in English)
Ovarian cancer is one of the most fatal malignant tumors that threaten women's health. The incidence rate is the third place among the female reproductive system malignant tumors, and the mortality rate ranks the first in gynecologic malignancies, the majority of patients have advanced diseases at the time of diagnosis. This observational study is to evaluate the safety and efficacy of senaparib in ovarian cancer patients under real conditions, especially in various subgroups of ovarian cancer patients, in order to provide information about treatment modes for ovarian cancer patients in real-world diagnosis and treatment。
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 500 (estimated)
- First submitted
- 8 May 2026
- Start date
- 10 Jun 2026
- Primary completion date
- 31 Dec 2028
- Lead sponsor
- Zhejiang Cancer Hospital
- Diseases
- Ovarian cancer
- NCT number
- NCT07586449
What you commit to
- Study type: Observational
- Planned participants: 500
- From 10 Jun 2026 to the primary completion date, 31 Dec 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- There is evidence that the patient is a pregnant or lactating woman;
- Participating in any research with intervention measures other than routine -clinical practice;
- The researcher judges other situations that are not suitable for inclusion in the study;
Who the study is looking for
- Sign informed consent and voluntarily join the study;
- Epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer diagnosed by histology or cytology;
- -≥ 18 years old;
- The investigator determined that the patient could receive senaparib monotherapy or combination therapy;
- For patients with fertility, effective contraceptive methods should be used during the study period and within 90 days after the last administration of senaparib
Age in the registry: 18 years to - · Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Zhejiang Cancer Hospital Coordinator of this site? Confirm its status | Hangzhou | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.